Literature DB >> 28600595

Assessing behavioural changes in ALS: cross-validation of ALS-specific measures.

Marta Pinto-Grau1,2, Emmet Costello3,4, Sarah O'Connor3,4, Marwa Elamin3, Tom Burke3,4, Mark Heverin3, Niall Pender3,4, Orla Hardiman3.   

Abstract

The Beaumont Behavioural Inventory (BBI) is a behavioural proxy report for the assessment of behavioural changes in ALS. This tool has been validated against the FrSBe, a non-ALS-specific behavioural assessment, and further comparison of the BBI against a disease-specific tool was considered. This study cross-validates the BBI against the ALS-FTD-Q. Sixty ALS patients, 8% also meeting criteria for FTD, were recruited. All patients were evaluated using the BBI and the ALS-FTD-Q, completed by a carer. Correlational analysis was performed to assess construct validity. Precision, sensitivity, specificity, and overall accuracy of the BBI when compared to the ALS-FTD-Q, were obtained. The mean score of the whole sample on the BBI was 11.45 ± 13.06. ALS-FTD patients scored significantly higher than non-demented ALS patients (31.6 ± 14.64, 9.62 ± 11.38; p < 0.0001). A significant large positive correlation between the BBI and the ALS-FTD-Q was observed (r = 0.807, p < 0.0001), and no significant correlations between the BBI and other clinical/demographic characteristics indicate good convergent and discriminant validity, respectively. 72% of overall concordance was observed. Precision, sensitivity, and specificity for the classification of severely impaired patients were adequate. However, lower concordance in the classification of mild behavioural changes was observed, with higher sensitivity using the BBI, most likely secondary to BBI items which endorsed behavioural aspects not measured by the ALS-FTD-Q. Good construct validity has been further confirmed when the BBI is compared to an ALS-specific tool. Furthermore, the BBI is a more comprehensive behavioural assessment for ALS, as it measures the whole behavioural spectrum in this condition.

Entities:  

Keywords:  ALS; ALS-FTD-Q; BBI; Behaviour; Validation

Mesh:

Year:  2017        PMID: 28600595     DOI: 10.1007/s00415-017-8536-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  8 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI).

Authors:  Marwa Elamin; Marta Pinto-Grau; Tom Burke; Peter Bede; James Rooney; Meabhdh O'Sullivan; Katie Lonergan; Emma Kirby; Emma Quinlan; Nadia Breen; Alice Vajda; Mark Heverin; Niall Pender; Orla Hardiman
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-11-28       Impact factor: 4.092

3.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

Review 4.  The frontotemporal dementia-motor neuron disease continuum.

Authors:  James R Burrell; Glenda M Halliday; Jillian J Kril; Lars M Ittner; Jürgen Götz; Matthew C Kiernan; John R Hodges
Journal:  Lancet       Date:  2016-03-14       Impact factor: 79.321

5.  The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS.

Authors:  Joost Raaphorst; Emma Beeldman; Ben Schmand; Joris Berkhout; Wim H J P Linssen; Leonard H van den Berg; Yolande A Pijnenburg; Hepke F Grupstra; Janneke G Weikamp; H Jurgen Schelhaas; Janne M Papma; John C van Swieten; Marianne de Visser; Rob J de Haan
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

6.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

Authors:  Katya Rascovsky; John R Hodges; David Knopman; Mario F Mendez; Joel H Kramer; John Neuhaus; John C van Swieten; Harro Seelaar; Elise G P Dopper; Chiadi U Onyike; Argye E Hillis; Keith A Josephs; Bradley F Boeve; Andrew Kertesz; William W Seeley; Katherine P Rankin; Julene K Johnson; Maria-Luisa Gorno-Tempini; Howard Rosen; Caroline E Prioleau-Latham; Albert Lee; Christopher M Kipps; Patricia Lillo; Olivier Piguet; Jonathan D Rohrer; Martin N Rossor; Jason D Warren; Nick C Fox; Douglas Galasko; David P Salmon; Sandra E Black; Marsel Mesulam; Sandra Weintraub; Brad C Dickerson; Janine Diehl-Schmid; Florence Pasquier; Vincent Deramecourt; Florence Lebert; Yolande Pijnenburg; Tiffany W Chow; Facundo Manes; Jordan Grafman; Stefano F Cappa; Morris Freedman; Murray Grossman; Bruce L Miller
Journal:  Brain       Date:  2011-08-02       Impact factor: 13.501

7.  A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival.

Authors:  Tom Burke; Marta Pinto-Grau; Katie Lonergan; Peter Bede; Meabhdh O'Sullivan; Mark Heverin; Alice Vajda; Russell L McLaughlin; Niall Pender; Orla Hardiman
Journal:  Ann Clin Transl Neurol       Date:  2017-04-11       Impact factor: 4.511

8.  Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010.

Authors:  James Rooney; Susan Byrne; Mark Heverin; Bernie Corr; Marwa Elamin; Anthony Staines; Ben Goldacre; Orla Hardiman
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

  8 in total
  2 in total

1.  Loss of "insight" into behavioral changes in ALS: Differences across cognitive profiles.

Authors:  Anna G M Temp; Elisabeth Kasper; Stefan Vielhaber; Judith Machts; Andreas Hermann; Stefan Teipel; Johannes Prudlo
Journal:  Brain Behav       Date:  2021-12-02       Impact factor: 2.708

2.  Group interventions for amyotrophic lateral sclerosis caregivers in Ireland: a randomised controlled trial protocol.

Authors:  Tom Burke; Jennifer Wilson O'Raghallaigh; Sinead Maguire; Miriam Galvin; Mark Heverin; Orla Hardiman; Niall Pender
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.